| Allopurinol to reduce cardiovascular morbidity and mortality: A systematic review and meta-analysis KH van der Pol, KE Wever, M Verbakel, FLJ Visseren, JH Cornel, ... PLoS One 16 (12), e0260844, 2021 | 18 | 2021 |
| Dutch pharmacogenetics working group guideline for the gene-drug interaction of ABCG2, HLA-B and Allopurinol, and MTHFR, folic acid and methotrexate KH van der Pol, M Nijenhuis, B Soree, NJ de Boer-Veger, AM Buunk, ... European Journal of Human Genetics 32 (2), 155-162, 2024 | 11 | 2024 |
| Drug repurposing of generic drugs: challenges and the potential role for government KH van der Pol, M Aljofan, O Blin, JH Cornel, GA Rongen, ... Applied Health Economics and Health Policy 21 (6), 831-840, 2023 | 6 | 2023 |
| Urate transporters may contribute to the difference in cardiovascular outcome between allopurinol and febuxostat K Van der Pol, J Koenderink, J Van den Heuvel, P Van den Broek, ... European Journal of Clinical Pharmacology 78 (SUPPL 1), S104-S104, 2022 | 2 | 2022 |
| Cardiovascular risk in gout-Role of allopurinol? ICA de Jong, N van Herwaarden, GA Rongen, KH van der Pol Nederlands Tijdschrift Voor Geneeskunde 165, D5273-D5273, 2021 | | 2021 |
